TY - JOUR
T1 - Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies
AU - Frumovitz, Michael
AU - Sood, Anil K.
N1 - Funding Information:
Portions of work in this paper were supported by NIH grants (CA 11079301 and CA 10929801), the U.T. M. D. Anderson Ovarian Cancer SPORE (P50 CA083639), the Ovarian Cancer Research Fund, Inc., and The Marcus Foundation.
PY - 2007/3
Y1 - 2007/3
N2 - Vascular endothelial growth factor (VEGF) plays a critical role in angiogenesis, which is required for tumor growth and metastasis. In this article, a review of the functional and biological roles of the VEGF pathway in driving angiogenesis and growth of gynecologic malignancies was performed. Based on the biological functions of VEGF, multiple approaches for targeting the VEGF/VEGF-receptor complex have been developed and many of these have demonstrated substantial activity in preclinical models. These promising data have led to rapid clinical development of VEGF-targeted agents. Therefore, we also assessed the status of VEGF-targeted therapies and associated toxicities in gynecologic malignancies. However, many questions remain related to optimal dosing, sequencing of therapies, management of toxicities, appropriate patient selection, and assessment of response, which will require further studies. Nevertheless, VEGF-targeted therapies offer hope for improving the outcome of cancer patients.
AB - Vascular endothelial growth factor (VEGF) plays a critical role in angiogenesis, which is required for tumor growth and metastasis. In this article, a review of the functional and biological roles of the VEGF pathway in driving angiogenesis and growth of gynecologic malignancies was performed. Based on the biological functions of VEGF, multiple approaches for targeting the VEGF/VEGF-receptor complex have been developed and many of these have demonstrated substantial activity in preclinical models. These promising data have led to rapid clinical development of VEGF-targeted agents. Therefore, we also assessed the status of VEGF-targeted therapies and associated toxicities in gynecologic malignancies. However, many questions remain related to optimal dosing, sequencing of therapies, management of toxicities, appropriate patient selection, and assessment of response, which will require further studies. Nevertheless, VEGF-targeted therapies offer hope for improving the outcome of cancer patients.
KW - Angiogenesis
KW - Gynecologic cancer
KW - Vascular endothelial growth factor (VEGF)
UR - http://www.scopus.com/inward/record.url?scp=33846933952&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33846933952&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2006.10.062
DO - 10.1016/j.ygyno.2006.10.062
M3 - Review article
C2 - 17306693
AN - SCOPUS:33846933952
SN - 0090-8258
VL - 104
SP - 768
EP - 778
JO - Gynecologic oncology
JF - Gynecologic oncology
IS - 3
ER -